Company Insights

LNTH supplier relationships

Explore interactive graphBrowse insights index
LNTH supplier relationship map

Lantheus (LNTH) — supplier map, strategic constraints, and investor implications

Lantheus operates as a vertically integrated radiopharmaceutical company that monetizes through sale of diagnostic and therapeutic imaging agents while outsourcing critical manufacturing inputs. The company sources bulk radioisotopes and finishes several products through third‑party manufacturers and service providers, capturing margin on branded diagnostics and therapeutics while depending on a concentrated set of upstream suppliers for supply continuity. For investors evaluating supplier relationships, the key lens is concentration and operational criticality: supply interruptions for Mo‑99 or sole‑source manufactured products directly translate into revenue and execution risk. Learn more at https://nullexposure.com/.

Why supplier relationships matter for valuation and operations

Lantheus’s business model mixes high-margin proprietary imaging products with operational exposure to a thin global supplier base for radioisotopes and specialized manufacturing. When upstream suppliers are few and some roles are sole‑source, the company’s delivery and revenue profile becomes more directly tied to counterparty stability and contract terms. Investors should price an explicit premium for concentration risk and for the operational complexity of handling time‑sensitive radioisotopes.

Explore deeper supplier intelligence at https://nullexposure.com/.

What Lantheus’s filings and recent press disclose — relationship by relationship

Jubilant HollisterStier LLC (Jubilant / JHS)

Lantheus has a Manufacturing and Supply Agreement with Jubilant HollisterStier effective February 23, 2022 for manufacture of DEFINITY, CARDIOLITE, NEUROLITE and evacuation vials, with NEUROLITE and several components sourced on a sole‑source basis. According to Lantheus’s FY2024 10‑K, Jubilant is a significant manufacturer and sole‑source for key products, making this a high‑criticality manufacturing relationship (FY2024 10‑K).

JHS (symbol JHS)

A duplicate 10‑K entry references the same Manufacturing and Supply Agreement executed in February 2022 for the same portfolio of products; this is the same counterparty noted above and reinforces the legal contract basis for the manufacturing arrangement (FY2024 10‑K).

ANSTO

Lantheus purchases finished Mo‑99 from ANSTO, one of the three global processing sites the company relies upon for this critical isotope. The FY2024 10‑K lists ANSTO as a major Mo‑99 supplier and therefore part of a very small, global upstream supply network (FY2024 10‑K).

Australian Nuclear Science and Technology Organisation (ANSTO)

The filing repeats that Lantheus sources finished Mo‑99 from the Australian Nuclear Science and Technology Organisation, underscoring ANSTO’s role in the company’s Mo‑99 procurement strategy and the global footprint of suppliers (FY2024 10‑K).

NTP Radioisotopes (NTP)

NTP in South Africa is cited as one of the three global processing sites Lantheus uses to obtain finished Mo‑99, placing it in the small set of high‑criticality upstream suppliers for radioisotope supply (FY2024 10‑K).

NTP (symbol NTPI)

A second 10‑K row identifies NTP with the inferred symbol NTPI, again confirming the company’s purchase of Mo‑99 from NTP and reiterating NTP’s place in the limited global pool of Mo‑99 processors (FY2024 10‑K).

Institute for Radioelements (IRE)

IRE in Belgium is named as one of the three main processing sites from which Lantheus purchases finished Mo‑99, establishing IRE as a core upstream supplier for a product that underpins many imaging procedures (FY2024 10‑K).

IRE (symbol IRE)

The filing also lists IRE with an inferred ticker, reinforcing the contractual and operational recognition of IRE as a principal Mo‑99 source in the company’s supply chain disclosures (FY2024 10‑K).

Framatone‑CERCA

Framatone‑CERCA is identified in filings as the fabricator of uranium targets and, in some cases, research reactor fuel — a critical upstream supplier to most global Mo‑99 producers rather than to Lantheus directly, making Framatone‑CERCA a second‑tier but structurally important participant in the Mo‑99 ecosystem (FY2024 10‑K).

Life Molecular Imaging

In 2026 Lantheus acquired global rights to Life Molecular Imaging’s RM2 radiotherapeutic and radiodiagnostic pair (177Lu‑DOTA‑RM2 and 68Ga‑DOTA‑RM2), expanding its therapeutic pipeline and bringing a newly acquired product and associated supplier commitments in‑house under Lantheus control (ITN Online, March 2026).

AstraZeneca

A FY2026 market report noted an increase related to a payment to AstraZeneca to reduce future royalty obligations for NAV‑4694 and milestone payments tied to RM2, indicating financial settlement activity that affects cost of goods and future margin profiles tied to acquired programs (Zacks, FY2026 coverage).

Solomon Partners Securities, LLC

Solomon Partners served as financial advisor to Lantheus in the SPECT business sale transaction announced in 2026, indicating the use of boutique investment banking advice for corp‑dev execution (CityBiz, March 2026).

Foley Hoag LLP

Foley Hoag acted as legal advisor to Lantheus in the 2026 SPECT divestiture, reflecting external legal counsel engagement for transaction execution and regulatory considerations (CityBiz, March 2026).

Ropes & Gray LLP

Ropes & Gray served as an additional legal advisor on the SPECT sale, confirming the multi‑firm legal advisory structure on strategic transactions (CityBiz, March 2026).

Ernst & Young LLP

Ernst & Young acted as Lantheus’s financial and tax advisor on the SPECT business sale, evidencing reliance on external professional services for tax optimization and deal accounting (CityBiz, March 2026).

Operational constraints and what they imply for investors

  • Concentration and criticality: The company discloses reliance on three global Mo‑99 processing sites and on Jubilant as a sole‑source manufacturer for several finished products. This creates high operational concentration and converts supplier outages into potential revenue interruption (company FY2024 10‑K).
  • Global supply fragility: Lantheus explicitly calls the Mo‑99 supply fragile and unstable, signaling a persistent external supply risk that is geographically global in nature and not mitigable by simple local substitution (company FY2024 10‑K).
  • Contracting posture and maturity: Several supplier relationships (e.g., Mo‑99 agreements with IRE, NTP and ANSTO) include defined contract terms through end of 2025 with renewals and termination mechanics; the company also maintains formal manufacturing and supply agreements with Jubilant, reflecting standardized contracting but finite term exposure (company FY2024 10‑K).
  • Service providers for transactions: Use of multiple financial and legal advisors for the SPECT divestiture indicates mature corporate governance and external advisory reliance for capital allocation decisions (CityBiz, March 2026).

Explore structured supplier intelligence and how it affects portfolio risk at https://nullexposure.com/.

Investment implications and portfolio actions

  • Valuation impact: Price a supply‑concentration discount into multiples until Mo‑99 and finished‑product manufacturing risks are demonstrably diversified or hedged.
  • Catalyst watch: Monitor contract renewals with IRE, NTP and ANSTO, and any capacity expansions or vertical integration moves that reduce sole‑source dependence.
  • Risk management: Stress‑test revenue under partial Mo‑99 outage scenarios given the time‑sensitive nature of isotope logistics.

Conclusion — what investors should do next

Lantheus delivers differentiated products and growth via acquisitions, but the business remains operationally sensitive to a narrow set of suppliers and sole‑source manufacturers, making supplier monitoring a priority for risk‑adjusted valuation. For subscription‑grade supplier maps and real‑time relationship tracking that feed investment decisions, visit https://nullexposure.com/.